Medicine Recommendations

Various indications

The colour classification is dependant on the indication. See LMWH Summary Prescribing Guide for more details. 

Schizophrenia or bipolar disorder (NICE TA286 - terminated appraisal)

NICE TA286 - Loxapine Inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)

Treatment of schizophrenia in adults aged 18 and over

For treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Age Related Macular Degeneration

Constipation in adults

Constipation in children

Treatment & prevention of magnesium deficiency

Insomnia in those over 55 (short term use only)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

For the Treatment of Rapid Eye Movement (REM) Sleep Behaviour Disorder (RBD) in Parkinson’s Disease and Lewy Body Dementia

Children with learning disabilities

Children with ADHD

Children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome

Cerebral palsy

Children with complex neurodevelopmental disorders that the specialist considers eligible

All indications including insomnia and jet lag

For the management of sleep disturbance in adult patients with ADHD

Alzheimer's Dementia (NICE TA217)

NICE TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

MHRA Drug Safety Update - Memantine pump device (Ebixa): risk of medication errors

Short term use in anxiety

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Ocular symptoms of cystinosis

Ulcerative colitis and Crohn's ONLY; only for inflammatory bowel diseases when patients are unable to tolerate azathioprine.

**Please note - For Blackpool, Fylde & Wyre CCGs DMARD Shared Care Guidelines please use the versions available on the CCG website

Ulcerative colitis

Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with implied Glucose Tolerance and/or increased HbA1C who are at high risk for developing overt type 2 diabetes mellitus and still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3-6 months

Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control